Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Decreases By 23.9%

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 995,395 shares, a drop of 23.9% from the February 26th total of 1,307,493 shares. Currently, 3.2% of the company’s shares are short sold. Based on an average daily volume of 1,654,814 shares, the short-interest ratio is presently 0.6 days.

Liminatus Pharma Stock Performance

Shares of NASDAQ LIMN opened at $0.19 on Friday. The company’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.92. Liminatus Pharma has a 52-week low of $0.18 and a 52-week high of $33.66. The company has a market capitalization of $5.82 million and a P/E ratio of -1.56.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma currently has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.